25 Years of p53 Research

1. Front Matter

   Pages i-xii

   PDF

2. The First Twenty-Five Years of p53 Research

   • Harlan Robins, Gabriela Alexe, Sandra Harris, A. J. Levine

   Pages 1-25

3. Regulation of p53 DNA Binding

   • Kristine McKinney, Carol Prives

   Pages 27-51

4. 20 Years of DNA Damage Signaling to p53

   • Kevin G. McLure, Michael B. Kastan

   Pages 53-71

5. Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX

   • Geoffrey M. Wahl, Jayne M. Stommel, Kurt Krummel, Mark Wade

   Pages 73-113

6. Regulation of the p53 Response by Cellular Growth and Survival Factors

   • Lauren Brown, Samuel Benchimol

   Pages 115-140

7. P53, Cell Cycle Arrest and Apoptosis

   • Shulin Wang, Wafik S. El-Deiry

   Pages 141-163

8. P53 Has a Direct Pro-apoptotic Action at the Mitochondria

   • Ute M. Moll

   Pages 165-181

9. Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor

   • Lawrence A. Donehower, Dora Bocangel, Melissa Dumble, Guillermina Lozano

   Pages 183-207

10. P53, P63, and P73: Internecine Relations?

    • Frank McKeon, Annie Yang

    Pages 209-222

11. P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells

    • Olimpia Monti, Alexander Damalas, Sabrina Strano, Giovanni Blandino

    Pages 223-232

12. P53: Gatekeeper, Caretaker or Both?

    • Carlos P. Rubbi, Jo Milner

    Pages 233-253

13. Analysis of p53 Gene Alterations in Cancer: A Critical View

    • Thierry Soussi

    Pages 255-292

14. Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection

    • Hong Shi, Florence Le Calvez, Magali Olivier, Pierre Hainaut

    Pages 293-319

15. Prognostic and Predictive Value of TP53 Mutations in Human Cancer

    • Magali Olivier, Pierre Hainaut, Anne-Lise Børresen-Dale

    Pages 321-338

16. P53 Links Tumor Development to Cancer Therapy

    • Michael T. Hemann, Scott W. Lowe

    Pages 339-351

17. Novel p53-Based Therapies: Strategies and Future Prospects

    • Sonia Lain, David Lane

    Pages 353-376

18. Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue

    • Andreas C. Joerger, Assaf Friedler, Alan R. Fersht

    Pages 377-397

19. Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy

    • Galina Selivanova, Vladimir J. N. Bykov, Klas G. Wiman

    Pages 399-419

20. Novel Approaches to p53-Based Therapy: ONYX-015

    • Frank McCormick

    Pages 421-429

1. Communication, awareness and access to information: Given the complexity of the field and the fact that data pertaining to each particular aspects of p53 biology or deregulation are scattered in many different publications, it is extremely difficult to access the full scale of relevant information of any specific p53-related topic. Review arcticles, despite their fundamental role in disseminating knowledge, usually focus only on general mechanisms and do not discuss in detail the many variations that can occur with respect to cell type, particular mutation type, as well as biological activation context. Books such as this one may help in this task by putting into perspective both general considerations on the p53 pathway and more specific information on various aspects of p53. In the longer term, however, open access to p53 complexity will require the development of knowledge bases accessible through the web and using simple navigation tools to guide users towards the specific information they need. Several efforts are currently being developed in that direction. They need to be strenghtened and better integrated within the rapidly growing galaxy of web-based information sources on molecular and individual variations in cancer. 2. Reference functional assays and structural analysis: Given the huge diversity of cellular and animal models for wild-type or mutant p53 functions, it will be important to set up standard, universally accepted assays to measure critical p53 protein functions.

• DNA
• P53, Wiman, Hainaut, tumor suppressor genes, apoptosis, muta
• apoptosis
• biology
• cancer
• cancer research
• cancer therapy
• cell
• genes
• molecular biology
• mutagen
• oncogene
• protein
• regulation
• tumor

• International Agency for Research on Cancer, World Health Organization, France

  Pierre Hainaut

• Cancer Center Karolinska, Karolinska Institute, Sweden

  Klas G. Wiman

Policies and ethics